In context
Survodutide was tested in a 48-week phase 2 trial in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis and liver fibrosis. [1]
At a glance
- Type
- Peptide / related clinical research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- Histological liver outcomes in a selected trial population are distinct from long-term disease complications and regulatory authorisation.
How to interpret this evidence
Histological liver outcomes in a selected trial population are distinct from long-term disease complications and regulatory authorisation. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. pubmed.ncbi.nlm.nih.gov